Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessAuthor Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
-
Article
Open AccessPRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
Tumor-specific antibody drugs can serve as cancer therapy with minimal side effects. A humanized antibody, PRL3-zumab, specifically binds to an intracellular oncogenic phosphatase PRL3, which is frequently exp...